A COMPARATIVE REVIEW OF THE ADVERSE-EFFECTS OF TREATMENTS FOR HYPERLIPEMIA

被引:38
作者
STEINER, A
WEISSER, B
VETTER, W
机构
[1] Department of Internal Medicine, Universitätsspital Zürich, Zürich, CH-8091
关键词
D O I
10.2165/00002018-199106020-00003
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Various lipid-lowering drugs have been shown to reduce serum cholesterol and serum triglycerides effectively. In view of trials indicating that lipid-lowering drugs may reduce cardiac morbidity and mortality but not the overall mortality in the study group, increased attention must be focused on potential harmful side effects during treatment with these agents. The adverse effects of many of the principal drugs in this category are discussed. Gastrointestinal symptoms, usually self-limited and reversible, are the most common side effects. Potential harmful adverse effects include drug interactions (cholestyramine), myopathy and hepatic injury (HMG-CoA reductase inhibitors), and increased gallstone formation and ventricular arrhythmias (clofibrate). Not all lipid-lowering drugs have been studied adequately on a long term basis, so that medications given for an indefinite period must be reevaluated frequently. However, there are several agents that lower serum lipid levels effectively and that have been used for more than 20 years without serious side effects.
引用
收藏
页码:118 / 130
页数:13
相关论文
共 114 条
[1]  
Andersson R.G., Aberg G., Brattsand R., Ericsson E., Landholm L., Studies on the mechanism of flush induced by nicotinic acid, Acta Pharmacologics et Toxicologica, 41, pp. 1-10, (1977)
[2]  
Barber M., Mueller T., Gilmour R.F., Ziper D.P., Electrophysiologic effects of prubucol on monkey ventricle, Abstract. Circulation, 64, 4, (1981)
[3]  
Beil U., Crouse J.R., Einarsson K., Grundy S.M., Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-lipoprotein triglycérides, Metabolism, 31, pp. 438-444, (1982)
[4]  
Berkowitz D., Selective blood lipid reductions by newer pharmacologic agents, American Journal of Cardiology, 2, pp. 834-840, (1964)
[5]  
Bilheimer D.W., Grundy S.M., Brown M.S., Goldstein J.L., Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholestero-lemia hétérozygotes, Proceedings of the National Academy of Sciences of the United States of America, 80, pp. 4124-4128, (1983)
[6]  
Bjornsson T.D., Mellin P.J., Blaschke T.F., Interaction of clofibrate with warfarin: I. Effects of clofibrate on the disposition of en-antiomorphs of warfarin, Journal of Pharmacokinetics and Biopharmacology, 5, pp. 495-505, (1977)
[7]  
Blum C.B., Levy R.I., Eisenberg S., Hall M., Goebel R.H., Et al., High density lipoprotein metabolism in man, Journal of Clinical Investigation, 60, pp. 795-807, (1977)
[8]  
Boberg M., Vessby B., Selinus I., Effects of dietary supplementation with n-6 and n-3 long chain polyunsaturated fatty acids on serum lipoproteins and platelet function in hypertriglyceri-demic patients, Acta Medica Scandinavica, 220, pp. 153-160, (1986)
[9]  
Brensike J.F., Levy R.I., Kelsey S.F., Passamani E.R., Richardson J.M., Et al., Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI type II coronary intervention study, Circulation, 69, pp. 313-324, (1984)
[10]  
Brown D.D., Juhl R.P., Warner S.L., Decreased bioavailability of digoxin due to hypocholesterolemic interventions, Circulation, 69, pp. 164-172, (1978)